ProCE Banner Activity

SUSTAIN Subgroup Analysis: Time to First Sickle Cell–Related Pain Crisis in Patients With SCD Receiving Crizanlizumab vs Placebo

Slideset Download
Conference Coverage
In this subgroup analysis of a phase II study, high-dose crizanlizumab delayed sickle cell–related pain crises across all defined subgroups of patients with sickle cell disease.

Released: December 12, 2017

Expiration: December 11, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Novartis Pharmaceuticals Corporation